A pioneering treatment to cure a 44-year-old British man with HIV has been adjudged to be remarkably effective.
News report has it that the doctors handling the treatment had said there has been “remarkable” progress and has described the breakthrough as “one of the first serious attempts at a full cure for HIV”. Results showed the man’s most recent blood test showed no detectable HIV was present.
The treatment procedure which is still on trial stage employs what is termed two-stage attack on the killer virus and 50 persons have been earmarked to complete this trial. The British man is the first among the 50 persons to undergo the two-stage clinical treatment successfully.
Five top British Universities namely; Oxford and Cambridge universities, Imperial College London, University College London, and King’s College London are involved in the research organised by the British National Health Service.
“This is one of the first serious attempts at a full cure for HIV. We are exploring the real possibility of curing HIV” Sunday Times was told by the Managing Director of the National Institute for Health Research Office for Clinical Research Infrastructure, Mr. Mark Samuels.
“This is a huge challenge and it’s still early days but the progress has been remarkable.” The 44-year-old British man confirmed to the newspaper that blood test carried out on him came out negative but was quick to add that it was too early to come to a final conclusion on the efficacy of the treatment.
The current method for HIV treatment that involves the use of antiretroviral (ART) therapies has not completely ride patients of the HIV virus since the virus find ways of hiding out of the drugs’ reach in the T-cells of the immune system.
The two-stage procedure will aim to completely clear the virus out the patient’s body which has been the major challenge to scientists for a number of years now.
The two-sage procedures refers to as “kick and kill” starts with a vaccine that locate infected T-cells which is then followed by a course of Vorinostat, a drug that awakens the dormant T-cells that consequently produce HIV proteins that act as a homing beacon to the immune system.
Professor Sarah Fidler, a consultant physician with Imperial College London said the treatment worked in the laboratory and there was “good evidence” it will work in patients but she thereafter added that “We must stress we are still a long way from any actual therapy.”
Photo Credit: Pixabay